Pure Global AI
NCT06228001Recruiting

Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.

Dr. Stéphanie DelstancheClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Amyotrophic Lateral Sclerosis
Drug/Device/Intervention
Actimyo
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Dr. Stéphanie Delstanche
Funder
Centre Hospitalier Régional de la Citadelle
Location
Liège, Belgium
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
Jan 01, 2028
Enrollment
30 participants
Primary outcome

Difference in 95th centile of stride velocity between baseline and one year follow up- or last time point,Difference in 50th centile of stride velocity between baseline and one year follow up- or last time point,Difference in 95th centile of stride length between baseline and one year follow up- or last time point,Difference in 50th centile of stride length between baseline and one year follow up- or last time point

Summary

ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS)
 may be included on a voluntary basis. The investigators plan to include a group of
 approximately 30 patients with ALS.
 
 The investigators have planned to assess patient every three months for a year. After each
 visit, participants will wear Actimyo for one month daily.

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06228001
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06228001 through Pure Global AI's free database. This phase not specified trial is sponsored by Dr. Stéphanie Delstanche and is currently Recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.